Safety
manic
ADVERSE EVENTS
No serious adverse events were observed in this trial, no psychotogenic effects were reported on the Brief Psychiatric Rating Scale, and no clinically significant manic symptoms were reported on the Young Mania Rating Scale. All participants scored 0 points in Clinician-Administered Dissociative States Scale at 2, 4, and 24 hours. At 40 minutes, participants in the esketamine-treated group showed higher level of dissociation compared with the midazolam control group (median [IQR] score, 0 [0-0] vs 6 [3-13]; 